The Cancer Treatment Centers of America Global, Inc., or CTCA, is an entire network of five hospitals located the U.S. cities of Atlanta, Philadelphia, Chicago, Tulsa and Phoenix. The CTCA have joined forces with WebMD to help provide up-to-date information for cancer patients to learn more about their treatment options, diagnoses, therapeutics, coping strategies and caregiver support.
The CTCA offer a welcoming experience and complete care for their cancer patients. Their dedicated team of experienced clinicians will help each patient fight the disease physically and mentally. They practice an integrative approach for the treatment of cancer that focuses on creating therapies to enhance the patient’s strength, stamina and their overall well-being. All of their medical centers have advanced technologies and options for combating cancer that include: radiation, chemotherapy, surgery and immunotherapy. CTCA also provide a wide range of clinical trials that are supported by nation’s top scientist and medical researchers.
Founded in 1988 by Richard J. Stephenson, CTCA hospitals have continued to offer tailored treatment plans to millions of patients living with the disease. Mr. Stephenson had introduced an eye-opening and comprehensive way for clinical professionals to progressively care for their cancer patients during their treatment process. The organization’s headquarters are currently based in Boca Raton, Florida. On April 20, 2015, CTCA had opened their first international office for patient concierge and general info, it is currently located in a neighborhood in Mexico City. CTCA still offer help to cancer patients located in various countries and allow them to receive care in their hospitals in the U.S.
Events that happen to us when we are young do a lot to shape our future. When Dr. Clay Siegall was a teenager, his father was diagnosed with cancer. He watched his father struggle so much with the sickness that when he finally passed away, he has already realized that he needed to do something about the Harshness of the cancer therapies used at the time. Clay attended college at the University of Maryland and attained a Bachelor of Science degree in Zoology. He then proceeded to the George Washington University and acquired his Ph.D. in genetics. After he graduated, he worked for some companies such as The National Cancer Institute and Bristol-Myers Squibb Pharmaceuticals.
Clay always knew that he wanted to establish his own company which would be a platform to advance his research in cancer therapies. He combined efforts with a friend, and together they founded Seattle Genetics in 1998. Clay says that he knew they needed a solid philosophy that the company would operate under. They decided that their primary focus would be helping their patients. They also wanted to emphasize intensive research and scientific innovation. The efforts the company had put in these three areas paid off handsomely when their first ADC drug, ADCETRIS, was approved for use by the FDA in 2011. The company has since marketed the drug in more than 65 countries, and they have plans to expand even further.
When asked whether Seattle Genetics has any plans of selling out, Clay says that he had held on to the company, and believed in it even when the funds were insufficient. He did both public and private fundraising for the future of the enterprise. Siegall says that now that they have made it to an internationally recognized brand, he is not willing to sell out. He added that the company’s primary goal was to help their patients, which had nothing to do with money, adding that in the absence of money, they have been able to give their best service to humanity. Clay is a real inspiration in the world of science and entrepreneurship.